Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

pfizer Developing Educational Initiatives for ALK+ Metastatic Non-small Cell Lung Cancer Tyrosine Kinase Inhibitors Therapy

Pfizer

General Area of Interest for this RFP: Projects that will be considered for Pfizer support will focus on increasing healthcare professional understanding and competence in one or more of the following areas:

• Addressing educational gaps in community oncology regarding the diagnosis, treatment, and management of patients with ALK-positive metastatic non-small cell lung cancer (ALK+ mNSCLC).

• Improving outcomes of ALK inhibitor-based treatments through effective management of adverse events, including timely identification, dose modifications and other innovative strategies.

• Assessing and managing specific adverse events related to ALK tyrosine kinase inhibitors (ALK TKIs): for example, weight gain, neurocognitive effects and other AEs of significance.

• Enhancing therapy management strategies for ALK inhibitors through collaboration between experts in academic centers and community oncologists.

• Preparing patients and care partners for ALK inhibitor therapy to evaluate tolerability and implement appropriate therapy management regimens.

• Optimizing collaboration and coordination of care among multidisciplinary teams, including pharmacists, nurses, and other allied health providers, during ALK inhibitor therapy.

Examples of educational formats that will be considered under this RFP include but are not limited to:
• Developing educational initiatives that empower patients to identify and actively report ALK TKI-related adverse events, thereby enhancing the accuracy and effectiveness of adverse event management and promoting treatment adherence.

• Creating podcasts and resources (digital and/or print) for patients and/or the allied healthcare team.

• Education on ALK TKI using online platforms with downloadable resources and reference tools for HCPs and/or patients can be explored.

Key Dates:

• RFP release date: January 21, 2025

• Grant Application due date April 15, 2025 o Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).

• Anticipated Grant Award Notification Date: June 13, 2025

• Grants will be distributed following a fully executed agreement.

• Anticipated Approximate Project Start and End Dates: July 2025 to Jan 2027 (18 months preferred maximum length; projects may be shorter than 18 months)

Specialties

Cancer

Public Health

Oncology

Pulmonology

Eligibility Requirements

Geographic Scope/Location of Project: Canada only

Applicant Eligibility Criteria

• Applicant organizations to this RFP must be based in Canada.

• The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to patient and/or healthcare professional education and/or healthcare improvement.

• Only organizations are eligible to receive grants, not individuals or physician-owned medical practices.

• If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role, and the requesting organization must have a key role in the project.

Eligible Countries:

Canada

Sponsor Details

Sponsor Institute/Organizations: Pfizer

Sponsor Type:

Address: 66 Hudson Boulevard East New York, NY 10001-2192 USA

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity